nach oben

Erschienen in:

01.06.2010 | Case Report

Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association

verfasst von: Masaru Togashi, Hideki Wakui, Koya Kodama, Yoshihiro Kameoka, Atsushi Komatsuda, Takashi Nimura, Ryo Ichinohasama, Ken-ichi Sawada

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

A 21-year-old man with lymphadenopathy and Coombs-positive hemolytic anemia had been treated with steroid maintenance therapy. He developed nephrotic syndrome with size increase of lymphadenopathy. Lymph node examination disclosed angioimmunoblastic T-cell lymphoma (AITL). Light microscopy of a renal biopsy specimen showed typical features of membranous nephropathy (MN), such as bubbling appearance and spike formation. Immunofluorescence studies revealed no significant deposition of immunoglobulins. Electron microscopy showed sparse degenerative materials on the epithelial side of the glomerular basement membranes, with intervening spikes. These unique histological findings suggested secondary MN. High-dose steroid therapy followed by six courses of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) therapy improved his symptoms. One-year follow-up revealed the patient in good health without any signs of relapse. Glomerular manifestations have rarely been reported in association with AITL. To our knowledge, this is the first reported case of nephrotic syndrome due to MN associated with AITL.

Dogan A, Gaulard P, Jaffe ES, Ralfkiaer E, Müller-Hermelink HK. Angioimmunoblastic T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 309–11.

Frizzera G, Moran EM, Rapparport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974;1:1070–3.CrossRefPubMed

Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin’s disease. New Engl J Med. 1975;292:1–8.PubMedCrossRef

Radaszkiewicz T, Lennert K. Immunoblastic adenopathy: clinical features, treatment and prognosis. Dtsch Med Wochenschr. 1975;100:1157–63 (in German with English abstract).CrossRefPubMed

Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol. 2003;121:681–91.CrossRefPubMed

Lachenal F, Berger F, Ghesquières H, Biron P, Hot A, Callet-Bauchu E, et al. Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore). 2007;86:282–92.CrossRef

Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de I’Adulte (GELA) trials. Blood. 2008;111:4463–70.CrossRefPubMed

Watanabe M, Shibaki H, Hayasaka T, Itoh T. A case of immunoblastic lymphadenopathy with immune-complex deposition of kidney biopsy specimen. Clin Immunol. 1978;10:967–76 (in Japanese with English abstract).

Staszewski H, Kumar G, Mishriki Y. Minimal change disease as the etiology of the nephrotic syndrome in a patient with angioimmunoblastic lymphadenopathy. Med Pediatr Oncol. 1988;16:206–9.CrossRefPubMed

10.

Yoshie T, Oguchi H, Furukawa T, Satoh K, Iwashita K, Saitoh H, et al. A case of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) associated with nephrotic syndrome which remitted after double filtration plasma pheresis (DFPP) therapy. Nippon Naika Gakkai Zasshi. 1988;77:1440–5 (in Japanese).PubMed

11.

De Samblanx H, Verhoef G, Zachée P, Vandenberghe P. A male with angioimmunoblastic T-cell lymphoma and proliferative glomerulonephritis. Ann Hematol. 2004;83:455–9.CrossRefPubMed

12.

Lim AKP, Ferreira MAS, Majumdar A, Wheeler DC, Lipkin GW. Renal amyloidosis and angioimmunoblastic lymphadenopathy. Nephrol Dial Transplant. 1998;13:453–4.CrossRefPubMed

13.

Wood WG, Harkins MM. Nephropathy in angioimmunoblastic lymphadenopathy. Am J Clin Pathol. 1979;71:58–63.PubMed

14.

Yamazaki Y, Inaba S, Nemoto T, Iizuka K, Fujikawa T, Horiguchi J, et al. Acute renal failure due to endocapillary proliferative glomerulonephritis in a patient with IBL-like T-cell lymphoma. Jpn J Clin Hematol. 1991;32:796–801 (in Japanese with English abstract).

15.

Duwaji MS, Shemin DG, Medeiros LJ, Esparza AR. Proliferative glomerulonephritis with unusual, organized, cylindrical deposits associated with angioimmunoblastic lymphadenopathy-like T-cell lymphoma. Arch Pathol Lab Med. 1995;119:377–80.PubMed

16.

Miura N, Suzuki K, Yoshino M, Kitagawa W, Yamada H, Ohtani H, et al. Acute renal failure due to IgM-λ glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-cell lymphoma. Am J Kidney Dis. 2006;48:e3–9.CrossRefPubMed

17.

Bhat JG, Kerpen HO, Murthy PS, Horowitz LJ, Valderrama E. Angioimmunoblastic lymphadenopathy, Bence Jones proteinuria, and acute renal failure. Arch Intern Med. 1981;141:1373–4.CrossRefPubMed

18.

Goto A, Takada A, Yamamoto S, Notoya A, Mukai M. Angioimmunoblastic T-cell lymphoma with renal involvement; a case report of direct bilateral kidney invasion by lymphoma cells. Ann Hematol. 2004;83:731–2.CrossRefPubMed

19.

Platzer E, von Roemeling R, Kaduk B, Meinl U. Disease-specific renal failure in angioimmunoblastic lymphadenopathy—remission by high dose prednisolone. Klin Wochenschr. 1981;59:509–16 (in German with English abstract).CrossRefPubMed

20.

Bignon YJ, Janin-Mercier A, Dubost JJ, Ristori JM, Fonck Y, Alphonse JC, et al. Angioimmunoblastic lymphadenopathy with dysproteinaemia (AILD) and sicca syndrome. Ann Rheum Dis. 1986;45:519–22.CrossRefPubMed

21.

Nakamoto Y, Hashimoto K, Chubachi A, Miura AB, Watanuki T, Konno A. Acute interstitial nephritis with symmetric enlargement of the lacrimal and salivary glands and systemic lymphadenopathy. Am J Nephrol. 1993;13:73–7.CrossRefPubMed

22.

Hamidou MA, El Kouri D, Audrain M, Grolleau J-Y. Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia. Ann Rheum Dis. 2001;60:293–5.CrossRefPubMed

23.

Søgaard PE, Molin J. Nephrocalcinosis in angioimmunoblastic lymphadenopathy. Acta Med Scand. 1982;211:319–20.PubMed

24.

Bello I, Paya C, Ruilope LM, Jimenez E, Rodicio JL. Angioimmunoblastic lymphadenopathy and transient Fanconi syndrome. Nephron. 1985;39:275–6.CrossRefPubMed

25.

Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med. 1986;80:63–70.CrossRefPubMed

26.

Da’as N, Polliack A, Cohen Y, Amir G, Darmon D, Kleinman Y, et al. Kidney involvement and renal manifestations in non-Hodgkin’s lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol. 2001;67:158–64.CrossRefPubMed

27.

Ponticelli C. Membranous nephropathy. J Nephrol. 2007;20:268–87.PubMed

28.

Joh K, Taguchi T, Shigematsu H, Kobayashi Y, Sato H, Nishi S, et al. Proposal of podocytic infolding glomerulopathy as a new disease entity: a review of 25 cases from nationwide research in Japan. Clin Exp Nephrol. 2008;12:421–31.CrossRefPubMed

29.

Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int. 1997;51:270–6.CrossRefPubMed

30.

Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis. 2002;39:706–12.CrossRefPubMed

31.

Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004;19:574–9.CrossRefPubMed

32.

Törnroth T, Skrifvars B. The development and resolution of glomerular basement membrane changes associated with subepithelial immune deposits. Am J Pathol. 1975;79:219–36.PubMed

33.

Miura N, Mori Y, Yoshino M, Suga N, Kitagawa W, Yamada H, et al. Membranous nephropathy (bubbling appearance and spike formation) without immunoglobulin deposition in a patient with systemic lupus erythematosus. Clin Exp Nephrol. 2008;12:475–8.CrossRefPubMed

34.

Yamaguchi S, Kitagawa M, Inoue M, Tomizawa N, Kamiyama R, Hirokawa K. Cell dynamics and expression of tumor necrosis factor (TNF)-α, interleukin-6, and TNF receptors in angioimmunoblastic lymphadenopathy-type T cell lymphoma. Exp Mol Pathol. 2000;68:85–94.CrossRefPubMed

35.

Suranyi MG, Guasch A, Hall BM, Myers BD. Elevated levels of tumor necrosis factor-α in the nephrotic syndrome in humans. Am J Kidney Dis. 1993;21:251–9.PubMed

36.

Horii Y, Iwano M, Hirata E, Shiiki H, Fujii Y, Dohi K, et al. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int. 1993;43(Suppl 39):S71–5.

Titel: Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association
verfasst von: Masaru Togashi
Hideki Wakui
Koya Kodama
Yoshihiro Kameoka
Atsushi Komatsuda
Takashi Nimura
Ryo Ichinohasama
Ken-ichi Sawada
Publikationsdatum: 01.06.2010
Verlag: Springer Japan
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 3/2010
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-010-0266-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Systemic lupus erythematosus after thymectomy for myasthenia gravis: a case report and review of the literature

The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients

Enhanced expression of naofen in kidney of streptozotocin-induced diabetic rats: possible correlation to apoptosis of tubular epithelial cells

Coincident chronic inflammatory demyelinating polyneuropathy and focal segmental glomerulosclerosis: a common autoimmunity?

Increased Na reabsorption via the Na–Cl cotransporter in autosomal recessive pseudohypoaldosteronism